Abstract: In one aspect, a solar cell unit comprises a cell. The cell includes a cell substrate and a plurality of secondary grid lines disposed on a front surface of the cell substrate. The solar cell unit also comprises a plurality of conductive wires spaced apart from each other. The plurality of conductive wires intersects and is connected with the secondary grid lines. At least one secondary grid line has at least one gap located between adjacent conductive wires.

Abstract: A solar cell unit comprises a cell. The cell includes a cell substrate and a plurality of secondary grid lines disposed on a front surface of the cell substrate. The secondary grid lines comprises an edge secondary grid line adjacent to an edge of the cell substrate and a middle secondary grid line disposed inside of the edge secondary grid line. The at least one edge secondary grid line has a width greater than the middle secondary grid line. The solar cell unit also comprises a plurality of conductive wires spaced apart from each other. The plurality of conductive wires intersects and is connected with the secondary grid lines.

Abstract: A solar cell unit comprises a cell. The cell includes a cell substrate and a secondary grid line disposed on a front surface of the cell substrate. The solar cell unit also comprises a conductive wire intersecting and welded with the secondary grid line. The secondary grid line has a width in a welding position with the conductive wire greater than a width thereof in a non-welding position.

Abstract: Disclosed herein are compounds of Formula (I), wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and use of the compounds in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

Abstract: A high density server system is disclosed, each of the server nodes on the node back plate and the midplane is established with its separate information transmission channels without any interference to one another, assuring that the network of every such node has a sufficient bandwidth. For those management traffic network signals having a relatively smaller data amount, tracks are incorporated, assuring the technical efficacies of assuring a network transmission speed of the overall server and reducing a space taken up by the transmission tracks.

Abstract: In one aspect of the present invention, a stator of a linear compressor comprises first stator pieces that are circumferentially and sequentially arranged about an axial direction and are radially disposed, second stator pieces that are provided between outer parts of the adjacent first stator pieces, and an outer side, away from a motor axis, of the second stator pieces assembled at an outer circumference of the stator. The stator can reduce the magnetic losses of the stator caused by the gap, and improve the efficiency of the motor. It can also improve the performance, stability, durability and reliability of the linear compressor. It can also reduce the bulk of the linear compressor.

Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

Abstract: The invention relates to a drum baffle and a washing machine having the same. The drum baffle includes a sheath and a bottom plate. The sheath and the bottom plate form a cavity having a hollow structure. The drum baffle is made by injection molding using one or more polymer adsorption materials, which may be used as a washing medium. The cavity of the drum baffle is internally filled with solid particles. The drum baffle includes a plurality of holes defined for communicating with the cavity of the drum baffle and an inner space of the inner drum of the washing machine to allow washing water to flow through. The drum baffle assists laundry to be rolled inside the inner drum, where the drum baffle and the solid particles inside adsorb and absorb soil in the laundry so as to achieve better washing results.

Abstract: A method for processing information applied in a server and the corresponding server is described. The method is applied in a server that stores a file set including a plurality of stream media files. The method includes obtaining a transition parameter when a first terminal apparatus accesses a file set when the first terminal apparatus accesses stream media file in the file set; making statistics of transition probability of each stream media file in the file set transiting to the respective stream media files in the file set according to the transition parameter of at least one first terminal apparatus; determining a target stream media file that the first terminal apparatus accesses most frequently in the stream media files in the file set according to the transition probability; and transmitting the target stream media file to a second terminal apparatus.

Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and use of the compounds in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

Abstract: The invention, belongs to the field of wastewater treatment technology, is a two-phase anaerobic reactor enhanced by addition of zero valent iron (ZVI). In the reactor, 2˜4 ZVI-filling layers are settled in the middle of the anaerobic hydrolysis-acidification tank, the effluent of which is fed into the rear anaerobic methanogenic tank. The degradation of organics is effectively enhanced in the anaerobic hydrolysis-acidification tank with dosing of ZVI, which may produce more acetic acid that is a desired substrate for the subsequent methanogenesis. Meanwhile, the acidic environment of the hydrolysis-acidification tank is helpful for the dissolution of ZVI to maintain its activity. The reactor is reasonably designed with high performance and strong shock resistance in anaerobic treatment of various wastewaters. Tests in lab-scale showed that hydrolysis-acidification and methanogenesis in this combined system were significantly improved compared with a reference reactor without addition of ZVI.

Abstract: The present invention is directed to novel tricyclic heterocycles of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine.

Abstract: The invention, belongs to the field of wastewater treatment technology, is a two-phase anaerobic reactor enhanced by addition of zero valent iron (ZVI). In the reactor, 2˜4 ZVI-filling layers are settled in the middle of the anaerobic hydrolysis-acidification tank, the effluent of which is fed into the rear anaerobic methanogenic tank. The degradation of organics is effectively enhanced in the anaerobic hydrolysis-acidification tank with dosing of ZVI, which may produce more acetic acid that is a desired substrate for the subsequent methanogenesis. Meanwhile, the acidic environment of the hydrolysis-acidification tank is helpful for the dissolution of ZVI to maintain its activity. The reactor is reasonably designed with high performance and strong shock resistance in anaerobic treatment of various wastewaters. Tests in lab-scale showed that hydrolysis-acidification and methanogenesis in this combined system were significantly improved compared with a reference reactor without addition of ZVI.

Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

Abstract: The present invention is directed to novel tricyclic heterocycles of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein R2 is a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).

Abstract: The present invention provides a novel class of heterocyclic compounds of Formula (I) as modulators of gamma secretase, wherein the definitions of the variables of Formula (I) are defined herein, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.